TC-O 9311 |
| カタログ番号GC11522 |
TC-O 9311 は、39 nM の EC50 を持つ強力なオーファン G タンパク質共役受容体 139 (GPR139) アゴニストです 。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 444932-31-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TC-O 9311 is an agonist of the orphan G protein-coupled receptor GPR139 (EC50 = 39 nM in a calcium mobilization assay).[1] It is selective for GPR139 over a panel of 90 additional targets. TC-O 9311 (1 μM) inhibits cell death induced by 1-methyl-4-phenylpyridinium (MPP+), but not 6-hydroxydopamine, in primary dopaminergic midbrain neurons.[2]
Reference:
[1]. Shi, F., Shen, J.K., Chen, D., et al. Discovery and SAR of a series of agonists at orphan G protein-coupled receptor 139. ACS Med. Chem. Lett. 2(4), 303-306 (2011).
[2]. Bayer Andersen, K., Leander Johansen, J., Hentzer, M., et al. Protection of primary dopaminergic midbrain neurons by GPR139 agonists supports different mechanisms of MPP+ and rotenone toxicity. Front. Cell. Neurosci. 10:164, (2016).
| Cas No. | 444932-31-4 | SDF | |
| Chemical Name | (Z)-N'-((Z)-hydroxy(naphthalen-1-ylimino)methyl)-3,5-dimethoxybenzohydrazonic acid | ||
| Canonical SMILES | COC1=CC(OC)=CC(/C(O)=N/N/C(O)=N/C2=CC=CC3=CC=CC=C32)=C1 | ||
| Formula | C20H19N3O4 | M.Wt | 365.38 |
| 溶解度 | 14mg/mL in ethanol or in DMF, 11mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7369 mL | 13.6844 mL | 27.3688 mL |
| 5 mM | 0.5474 mL | 2.7369 mL | 5.4738 mL |
| 10 mM | 0.2737 mL | 1.3684 mL | 2.7369 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *